Literature DB >> 17892973

Continuous oral contraception: changing times.

Patricia J Sulak1.   

Abstract

Oral contraceptives (OCs) remain the most common method of reversible contraception. Despite lowering of oestrogen and progestin content, the same basic design of 21 combination oestrogen plus progestin pills followed by a week of placebo pills has remained. Numerous studies have now documented that the 21/7 regimen needs to be modified. The 7-day hormone-free interval (HFI) in today's low-dose OCs is associated with reduced pituitary-ovarian suppression, allowing for ovarian follicular development, endogenous oestradiol production and possible ovarian cyst formation and ovulation. The 7-day HFI is also associated with hormone withdrawal symptoms that can lead to discontinuation and unintended pregnancy. Modifications in OC regimens are now appearing on the market secondary to the accumulated scientific data on the disadvantages of low-dose 21/7 pills. This article will review the data on problems with standard OC regimens and modifications that can improve the efficacy and side-effect profile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892973     DOI: 10.1016/j.bpobgyn.2007.08.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  7 in total

1.  Oral contraceptives in migraine therapy.

Authors:  Gianni Allais; Ilaria Castagnoli Gabellari; Cristina De Lorenzo; Ornella Mana; Chiara Benedetto
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

2.  Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2010-06

3.  Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses.

Authors:  David J Cote; John L Kilgallon; Noah L A Nawabi; Hassan Y Dawood; Timothy R Smith; Ursula B Kaiser; Edward R Laws; JoAnn E Manson; Meir J Stampfer
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

Review 4.  Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents.

Authors:  Andrea J Rapkin; Judith A Mikacich
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

5.  Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg -levonorgestrel 0.09 mg for dysmenorrhea: A placebo-controlled, double-blind, randomized trial.

Authors:  Tasuku Harada; Mikio Momoeda
Journal:  Reprod Med Biol       Date:  2021-02-27

6.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

7.  Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen).

Authors:  Johannes Bitzer; Maria Jesusa Banal-Silao; Hans-Joachim Ahrendt; Jaime Restrepo; Marion Hardtke; Ulrike Wissinger-Graefenhahn; Dietmar Trummer
Journal:  Int J Womens Health       Date:  2015-05-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.